Schonfeld Strategic Advisors LLC Has $817,000 Stock Holdings in Scholar Rock Holding Co. (NASDAQ:SRRK)

Schonfeld Strategic Advisors LLC cut its stake in Scholar Rock Holding Co. (NASDAQ:SRRK - Free Report) by 88.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 18,900 shares of the company's stock after selling 141,253 shares during the quarter. Schonfeld Strategic Advisors LLC's holdings in Scholar Rock were worth $817,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. GAMMA Investing LLC raised its holdings in Scholar Rock by 51.8% in the 4th quarter. GAMMA Investing LLC now owns 788 shares of the company's stock valued at $34,000 after acquiring an additional 269 shares during the period. Global Retirement Partners LLC increased its stake in shares of Scholar Rock by 584.7% during the fourth quarter. Global Retirement Partners LLC now owns 897 shares of the company's stock worth $39,000 after purchasing an additional 766 shares during the period. Nisa Investment Advisors LLC lifted its holdings in Scholar Rock by 1,321.8% during the 4th quarter. Nisa Investment Advisors LLC now owns 1,109 shares of the company's stock worth $48,000 after purchasing an additional 1,031 shares during the last quarter. Amalgamated Bank boosted its stake in Scholar Rock by 30.6% in the 4th quarter. Amalgamated Bank now owns 2,643 shares of the company's stock valued at $114,000 after purchasing an additional 620 shares during the period. Finally, KBC Group NV bought a new position in Scholar Rock during the 4th quarter worth $131,000. Institutional investors and hedge funds own 91.08% of the company's stock.

Analyst Ratings Changes

Separately, Wedbush reissued an "outperform" rating and issued a $50.00 target price on shares of Scholar Rock in a research report on Tuesday, March 25th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $42.67.

Scholar Rock Price Performance

Shares of NASDAQ SRRK traded down $0.14 during mid-day trading on Friday, reaching $30.85. The company had a trading volume of 846,155 shares, compared to its average volume of 1,268,790. Scholar Rock Holding Co. has a one year low of $6.76 and a one year high of $46.98. The business's 50-day simple moving average is $31.63 and its 200 day simple moving average is $35.92. The company has a debt-to-equity ratio of 0.63, a quick ratio of 3.88 and a current ratio of 3.88. The firm has a market cap of $2.93 billion, a price-to-earnings ratio of -13.13 and a beta of 0.37.

Insider Activity

In other news, insider Mo Qatanani sold 68,510 shares of the business's stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $37.40, for a total transaction of $2,562,274.00. Following the completion of the transaction, the insider now owns 111,084 shares of the company's stock, valued at approximately $4,154,541.60. The trade was a 38.15 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Tracey Sacco sold 5,000 shares of the firm's stock in a transaction dated Friday, April 25th. The shares were sold at an average price of $32.83, for a total value of $164,150.00. Following the completion of the sale, the insider now directly owns 71,750 shares in the company, valued at $2,355,552.50. This trade represents a 6.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 255,231 shares of company stock worth $9,220,236. 13.30% of the stock is currently owned by corporate insiders.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.